文献速递新生儿儿童血液肿瘤与免疫

中国新生儿重症监护病房极早及超早产儿非红细胞血制品输注现状:2019年多中心横断面研究

[Non-erythrocyte blood products transfusion in very preterm and extremely preterm infants in Chinese neonatal intensive care units].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2022-01-01

基于中国新生儿协作网2019年57家NICU的6 598例出生胎龄<32周早产儿横断面研究,42.7%曾接受非红细胞血制品输注,超早产儿中达60.4%;白蛋白、人免疫球蛋白和血浆最常用,调整相关因素后各NICU间输注率差异仍有统计学意义。

要点

  • 近半数极早及超早产儿住院期间接受非红细胞血制品输注,超早产儿比例更高。
  • 白蛋白、人免疫球蛋白和血浆为最常用的非红细胞血制品。
  • 调整相关因素后各NICU间输注率差异仍有统计学意义,提示使用规范性有待探讨。

核心结论

  • 2019年中国NICU救治的极早及超早产儿中接近半数曾接受非红细胞血制品输注,各单位使用率存在巨大差异。

研究设计与样本

  • 基于中国新生儿协作网(CHNN)极早产儿队列的横断面研究,纳入2019年生后24 h内收入57家NICU、出生胎龄<32周且接受完整治疗的6 598例早产儿。

主要发现

  • 2 816例(42.7%)为输注组,输注次数为3(1,6)次。
  • 输注组出生胎龄更小(Z=17.62,P<0.01)、出生体重更低(t=18.64,P<0.01),小于胎龄、多胎及产房高级复苏比例更高(χ²=31.06、12.82、287.52,均P<0.01),女婴及本院出生比例更低(χ²=10.68、78.23,均P<0.01)。
  • 总人群中白蛋白使用率25.4%(1 674例)、人免疫球蛋白21.5%(1 417例)、血浆18.9%(1 245例)。
  • 901例超早产儿中60.4%(544例)输注过非红细胞血制品,次数4(2,8)次;5 697例极早产儿中39.9%(2 272例)输注过,次数3(1,6)次。
  • 病情危重和非危重组输注率分别为62.2%(1 693/2 723)和29.0%(1 123/3 875),输注次数分别为4(2,7)次和2(1,4)次;调整相关因素后各单位间输注率差异有统计学意义(校正χ²=153.48,P<0.01)。

临床怎么用

  • 临床需关注极早及超早产儿非红细胞血制品的高输注率及中心间差异,结合患儿胎龄、体重和病情危重程度评估输注必要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To describe the use of non-erythrocyte blood products transfusion in very preterm and extremely preterm infants in the neonatal intensive care units (NICU) of the Chinese Neonatal Network (CHNN) in 2019, to explore the disparity between different centers, and to further investigate the rationality and standardability of non-erythrocyte blood products transfusion. Methods: This was a cross-sectional study based on the CHNN cohort of very preterm and extremely preterm infants. All 6 598 infants with gestational age (GA)<32 weeks and admitted to the 57 NICU of CHNN within 24 h of life in 2019 were enrolled. Non-erythrocyte blood products included platelet, plasma, albumin, immunoglobulin, cryoprecipitate and prothrombin complex. Infants who received at least one type of non-erythrocyte blood products were defined in transfusion group. The comparison between infants with and without transfusion was done by t-test, rank-sum test or χ2 test as appropriate. Linear regression model was used to generate adjusted transfusion rate of each center, and to investigate the correlation between adjusted rate and center-level characteristics. Results: A total of 6 598 infants were enrolled in the study, with gestational age of 30.0 (28.7, 31.0) weeks and birth weight of (1 353±312) g, and 43.6 % (2 877) of them were female. Among them, 42.7% (2 816) infants were enrolled in transfusion group, with the times of transfusion as 3 (1, 6) times. Compared to the infants without any transfusion of non-erythrocyte blood products, those infants received transfusion had lower gestational age (Z=17.62, P<0.01), lower birth weight (t=18.64, P<0.01), higher proportion of small-for-gestation age (χ2=31.06, P<0.01), multiple birth (χ²=12.82, P<0.01) and intensive resuscitation in delivery room (χ²=287.52, P<0.01), as well as lower proportion of females (χ²=10.68, P<0.01) and even lower proportion of infants born in this hospital (χ²=78.23, P<0.01). Among the entire study population, albumin (25.4%, 1 674 cases), immunoglobulin (21.5%, 1 417 cases) and plasma (18.9%, 1 245 cases) were the most commonly used non-erythrocyte blood products. Overall, 60.4% (544/901) infants with gestational age <28 weeks received transfusion 4 (2, 8) times. A total of 39.9% (2 272/5 697) infants between 28-31weeks received non-erythrocyte blood products 3 (1, 6) times. The non-erythrocyte blood products transfusion rates of critically-ill and non-critically-ill infants were 62.2% (1 693/2 723) and 29.0% (1 123/3 875) respectively, and the transfusion times were 4 (2,7) and 2 (1,4) times. The transfusion rates varied significantly among different NICU, and the disparities remained obvious after adjustment (adjusted χ²=153.48, P<0.01). Conclusion: Near half of very preterm and extremely preterm infants admitted to Chinese NICU in 2019 receive non-erythrocyte blood products during hospitalization with significant disparities among different hospitals. 目的: 分析2019年中国新生儿协作网(CHNN)新生儿重症监护病房住院的极早及超早产儿非红细胞血制品的使用现状及单位间差异,为探讨输注合理性与规范性提供证据。 方法: 基于CHNN大规模极早产儿队列数据库进行横断面研究,纳入2019年生后24 h内收入CHNN 57家NICU治疗、出生胎龄<32周且接受完整治疗的6 598例早产儿。收集患儿一般情况,描述不同出生胎龄、不同病情危重程度早产儿非红细胞血制品(血小板、血浆、人免疫球蛋白、白蛋白、冷沉淀和凝血酶原复合物)的使用率及次数。输注过至少1种非红细胞血制品即为输注组。采用两独立样本t检验、秩和检验或χ²检验进行输注组和非输注组组间比较。使用线性回归模型对单位间输注率和单位特征进行相关性分析。 结果: 6 598例早产儿出生胎龄为30.0(28.7,31.0)周,出生体重为(1 353±312)g,女2 877例(43.6%)。2 816例(42.7%)早产儿为输注组,输注次数为3(1,6)次。与未输注组相比,输注组患儿出生胎龄更小(Z=17.62,P<0.01),出生体重更低(t=18.64,P<0.01),小于胎龄、多胎以及产房高级复苏比例均更高(χ²=31.06、12.82、287.52,均P<0.01),女婴比例以及本院出生比例则均更低(χ²=10.68、78.23,均P<0.01)。总研究人群中,使用率高的非红细胞血制品依次为白蛋白25.4%(1 674例)、人免疫球蛋白21.5%(1 417例)、血浆18.9%(1 245例)。901例超早产儿中,60.4%(544例)输注过非红细胞血制品,使用次数4(2,8)次;5 697例极早产儿中,39.9%(2 272例)输注过非红细胞血制品,使用次数3(1,6)次。病情危重和非危重组中非红细胞血制品输注率分别达62.2%(1 693/2 723)和29.0%(1 123/3 875),输注次数分别为4(2,7)次和2(1,4)次。57家NICU中,调整与非红细胞血制品输注相关的因素后,各单位间极早及超早产儿非红细胞血制品输注率差异有统计学意义(校正χ²=153.48,P<0.01)。 结论: 2019年中国NICU救治的极早及超早产儿中,接近半数曾接受非红细胞血制品输注,各单位非红细胞血制品使用率存在巨大差异。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhao P, Gu XY, Jiang SY, et al. [Non-erythrocyte blood products transfusion in very preterm and extremely preterm infants in Chinese neonatal intensive care units]. Zhonghua Er Ke Za Zhi. 2022. PMID: 35090224. doi:10.3760/cma.j.cn112140-20210625-00532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。